Skip Navigation

Thanh U. Barbie, MD


Surgical Oncology

Make an Appointment

Physician

  • Instructor in Surgery, Harvard Medical School

Centers/Programs

Clinical Interests

  • Breast cancer surgery
  • Inflammatory breast cancer
  • Novel therapies for breast cancer

Diseases Treated

Contact Information

  • Appointments617-632-2175 (new)
    617-632-5043 (follow-up)
  • Office Phone Number617-632-5043
  • Fax617-632-2495

Board Certification:

  • Obstetrics and Gynecology, 2009

Fellowship:

  • Washington University School of Medicine, Breast Surgical Oncology

Residency:

  • Brigham and Women's Hospital, Obstetrics and Gynecology

Medical School:

  • University of Vermont Medical School

Research

Masiakos PT, MacLaughlin DT, Maheswaran S, Teixiera J, Fuller AF Jr, Shah PC, Kehas DJ, Kenneally MK, Dombkowski DM, Ha(Barbie) TU, Preffer FI, Donahoe PK. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian Inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. Clin Cancer Res. 1999 Nov; 5(11): 3488-99.

1999

Segev DL, Ha(Barbie) TU, Tran TT, Kenneally M, Harkin P, Jung M, MacLaughin DT, Donahoe PK, Maheswaran S. Mullerian inhibiting substance inhibits breast cancer cell growth through an NFKappa B-mediated pathway. J Biol Chem. 2000 Sep 15; 275(37): 28371-9.

2000

Ha(Barbie) TU, Segev DL, Barbie D, Masiakos PT, Tran TT, Dombkowski D, Glander M, Clarke TR, Lorenzo HK, Donahoe PK, Maheswaran S. Mullerian inhibiting substance inhibits ovarian cell growth through an Rbindependent mechanism. J Biol Chem. 2000 Nov 24;275(47):37101-9.

2000

Hoshiya Y, Gupta V, Segev DL, Hoshiya M, Carey JL, Sasur LM, Tran TT, Ha(Barbie) TU, Maheswaran S. Mullerian Inhibiting Substance induces NFkBsignaling in breast and prostate cancer cells. Mol Cell Endocrinol. 2003; Dec15; 211 (1-2): 43-9.

2003

Barbie TU, Barbie DA, MacLaughlin DT, Maheswaran S, Donahoe PK. Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107. Proc Natl Acad Sci U S A. 2003;100(26):15601-6.

2003

Soysal SD, Muenst S, Barbie TU, Fleming T, Gao F, Spizzo G, Oertli D, Viehl CT, Obermann EC, Gillanders WE. EpCAM expression varies significantly and is differentially associated with prognosis in the luminal B HER2+, basal-like, and
HER2 intrinsic subtypes of breast cancer. Br J Cancer. 2013 Mar 21. doi: 10.1038/bjc.2013.80.

2013

Zhu Z, Aref A, Cohoon T, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, Maciag K, Chan EM, Silkworth W, Labowsky MT, Rozhansky L, Mesirov JP, Gillanders WE, Ogino S, Hacohen N, Gaudet S, Eck MJ, Engelman JA, Corcoran RB, Wong KK, Hahn WC, Barbie DA. Inhibition of KRAS-Driven Tumorigenicity by interruption of an Autocrine Cytokine Circuit. Cancer Discovery. 2014 Apr;
4(4): 452-65. doi: 10.1158/2159-8290. CD-13-0646.

2014

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Top